Johnson & Johnson's earnings call highlights robust financial performance, driven by strong growth in Pharmaceuticals (particularly COVID-19 vaccine sales) and Medical Devices.  Management projects continued growth, but acknowledges inflation and supply chain pressures, particularly in Consumer Health, and the impact of the Omicron surge on Medical Devices in the first half of 2022.  The company's  focus on M&A and innovation, including several new product introductions and advanced technological developments, suggests a strong short-term and long-term outlook.
[1]
